Laura Sanchez
Carlos III Health Institute
3 Papers
Laura Sanchez is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Randomized controlled trial & Meropenem. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial
Irja Lutsar,Corine Chazallon,Ursula Trafojer,Vincent Meiffredy de Cabre,Cinzia Auriti,Chiara Bertaina,Francesca Ippolita Calò Carducci,Fuat Emre Canpolat,Susanna Esposito,Isabelle Fournier,Maarja Hallik,Paul T. Heath,Mari-Liis Ilmoja,Mari-Liis Ilmoja,Elias Iosifidis,Jelena Kuznetsova,Laurence Meyer,Tuuli Metsvaht,Tuuli Metsvaht,George Mitsiakos,Zoi Dorothea Pana,Fabio Mosca,Lorenza Pugni,Emmanuel Roilides,Paolo Rossi,Kosmas Sarafidis,Laura Sanchez,Mike Sharland,Vytautas Usonis,Adilia Warris,Jean-Pierre Aboulker,Carlo Giaquinto +31 more
TL;DR: Meropenem as broad-spectrum antibiotic should be reserved for neonates who are more likely to have Gram-negative LOS, especially in NICUs where microorganisms producing ESBL and AmpC beta-lactamases are circulating.
Statins: Could an old friend help in the fight against COVID-19?
Raúl R. Rodrigues-Diez,Antonio Tejera-Muñoz,Laura Marquez-Exposito,Sandra Rayego-Mateos,Sandra Rayego-Mateos,Laura Sanchez,Vanessa Marchant,Lucía Tejedor Santamaria,Adrian M. Ramos,Adrian M. Ramos,Alberto Ortiz,Alberto Ortiz,Jesús Egido,Marta Ruiz-Ortega +13 more
TL;DR: The potential beneficial effects of statins in COVID‐19 patients are discussed based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information.
Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.
Irja Lutsar,Corine Chazallon,Ursula Trafojer,Vincent Meiffredy de Cabre,Cinzia Auriti,Chiara Bertaina,Francesca Ippolita Calò Carducci,Fuat Emre Canpolat,Susanna Esposito,Isabelle Fournier,Maarja Hallik,Paul T. Heath,Mari-Liis Ilmoja,Mari-Liis Ilmoja,Elias Iosifidis,Jelena Kuznetsova,Laurence Meyer,Tuuli Metsvaht,Tuuli Metsvaht,George Mitsiakos,Zoi Dorothea Pana,Fabio Mosca,Lorenza Pugni,Emmanuel Roilides,Paolo Rossi,Kosmas Sarafidis,Laura Sanchez,Mike Sharland,Vytautas Usonis,Adilia Warris,Jean-Pierre Aboulker,Carlo Giaquinto +31 more
TL;DR: It is suggested that meropenem as broad-spectrum antibiotic should be reserved for neonates who are more likely to have Gram-negative LOS, especially in NICUs where microorganisms producing extended spectrum- and AmpC type beta-lactamases are circulating.